SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
DYN

Dyne Therapeutics, Inc. (NASDAQ:DYN)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$15.50-$0.53 (-3.31%)
 
Market cap
$2.90B
Insider Score
Health Score
Analyst consensus
Listed since
Sep 17, 2020
Market Cap$2.90B-28.5%
Revenue (ttm)$0
Net Income-$604.92M-42.7%
EPS-$3.63+0.8%
Shares Out187.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,231,136
Open$15.91
Previous Close$16.03
Day's Range$15.41 - $16.48
52-Week Range$14.00 - $27.31
Beta1.21
AnalystsBuy
Price Target$36.88(+137.94%)
Earnings DateMar 1, 2027

About DYN

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Address
1560 Trapelo Road, Waltham, MA, 02451, US
Market Cap
2.90 billion
Employees
289
Industrial Classification
Biotechnology

Dyne Therapeutics, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
1st Percentile Overall Score
DYN InsiderScore:26 / 99

Dyne Therapeutics, Inc. scored higher than 1% of companies evaluated by InsiderBuying, and ranked 97th out of 103 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Dyne Therapeutics, Inc. bought $40.0K of stock across 1 purchase in the last 90 days, the largest of them $40.0K.

Stake Increase

The average purchase added about 10% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$76.83M
Bought
$40.00K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
6 Buy1 Hold1 SellAvg target $39.10 (+146.4%)

8 firms rating DYN in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From DYN’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-3.31%
5 Days
-8.39%
1 Month
-1.71%
6 Months
-10.77%
1 Year
-28.47%

$DYN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in DYN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by DYN's directors and management

Net Shares Purchased by Insiders−4M−2M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

DYN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

DYN Revenue by Segment

$75.92MTotal
Personnel related$32.27M42.50%
Stock-based compensation$16.21M21.35%
Facility-related and other$14.84M19.54%
Professional and consulting fees$12.61M16.61%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New DYN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to DYN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in DYN

XBIState Street SPDR S&P Biotech ETF$71.47M
VTIVanguard Morningstar Total Stock Market ETF$69.56M
IWMiShares Russell 2000 ETF$64.58M
VXFVanguard Extended Market ETF$35.48M
VBVanguard Morningstar Small-Cap ETF$31.51M
VBRVanguard Morningstar Small-Cap Value ETF$20.44M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from DYN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
25.01
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
50

News check: Coverage includes routine corporate filings and conference participation with no material catalysts, upgrades, downgrades, or earnings announcements directly impacting Dyne.

Recent Insider Activity

Buys
1
Sells
26
Buy Value
$40.00K
Distinct Buyers
1

Insider Score Trend Over Time

+25.0 since Sep 22
0255075100Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 19.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Oct 7 — Insider Score 37.6Oct 8 — Insider Score 37.5Oct 9 — Insider Score 37.4Oct 10 — Insider Score 37.0Oct 11 — Insider Score 38.1Oct 12 — Insider Score 38.0Oct 13 — Insider Score 37.8Oct 14 — Insider Score 37.4Oct 15 — Insider Score 37.4Oct 16 — Insider Score 37.1Oct 17 — Insider Score 37.0Oct 18 — Insider Score 37.4Oct 19 — Insider Score 37.2Oct 20 — Insider Score 37.2Oct 21 — Insider Score 37.0Oct 22 — Insider Score 37.3Oct 23 — Insider Score 37.0Oct 24 — Insider Score 37.0Oct 25 — Insider Score 36.6Oct 26 — Insider Score 36.7Oct 27 — Insider Score 36.8Oct 28 — Insider Score 36.8Oct 29 — Insider Score 36.6Oct 30 — Insider Score 35.5Oct 31 — Insider Score 35.0Nov 1 — Insider Score 35.4Nov 2 — Insider Score 35.3Nov 3 — Insider Score 34.0Nov 4 — Insider Score 34.1Nov 5 — Insider Score 32.9Nov 6 — Insider Score 32.1Nov 7 — Insider Score 31.4Nov 8 — Insider Score 32.3Nov 9 — Insider Score 33.6Nov 10 — Insider Score 32.4Nov 11 — Insider Score 31.5Nov 12 — Insider Score 31.5Nov 13 — Insider Score 30.4Nov 14 — Insider Score 29.5Nov 15 — Insider Score 30.0Nov 16 — Insider Score 29.4Nov 17 — Insider Score 28.2Nov 18 — Insider Score 27.5Nov 19 — Insider Score 26.3Nov 20 — Insider Score 25.0Nov 21 — Insider Score 24.4Nov 22 — Insider Score 25.0Sep 22Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBRNiShares Neuroscience and Healthcare ETF3.27%
SBIOALPS Medical Breakthroughs ETF2.08%
TSEET. Rowe Price Small Cap ETF1.89%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF1.75%
WDNAWisdomTree BioRevolution Fund1.37%
TDNAT. Rowe Price Biotech ETF1.33%
WSMDWasatch Small/Mid Cap ETF0.82%
XBIState Street SPDR S&P Biotech ETF0.75%
BBCVirtus Biotech Clinical Trials ETF0.73%
SGRWHarbor Active Small Cap Growth ETF (SGRW)0.54%
JDOCJPMorgan Healthcare Leaders ETF0.53%
TMIDT. Rowe Price Mid Cap Equity Research ETF0.52%

Weight is the stock’s share of each fund’s holdings.